secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2026-06-26T20:06:18+00:00
Accession:  0001437749-26-021832
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar reports ALXN1840 shows significant neurologic and global benefit in Phase 3 FoCus trial
--------------------------------------------------------------------------------

- ALXN1840 achieved significant neurologic improvement on UWDRS Part III (p=0.006) vs SOC (p=0.435) over 48 weeks.
- Global clinical improvement on CGI-I at Week 48 significantly greater with ALXN1840 vs SOC (p<0.001).
- Favorable safety profile: drug-related SAEs in 4.9% of patients, no treatment-related deaths.
- Results support planned NDA submission to FDA for ALXN1840 in mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926021832/0001437749-26-021832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926021832/mnpr20260625_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-021832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer